Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.
The effectiveness of treating human brucellosis caused by Brucella melitensis with a 6-week course of doxcycline plus streptomycin for 2 of those weeks was analyzed by a multicenter prospective study of 139 patients. Subjects with central nervous system involvement, endocarditis, or spondylitis were excluded from the study. All but 5 of the 139 patients completed the full treatment schedule and became afebrile in the first week of therapy. Four patients suffered relapses during the follow-up period. Of the five patients who did not complete the treatment, two left because of adverse secondary effects (1.4%), another two left for noncomplicance with the treatment (1.4%), and the remaining patient was considered a therapeutic failure because his symptoms persisted after the first week of therapy (0.7%). We concluded that the combination of doxycycline and streptomycin is an effective treatment for the types of brucellosis included in our study.
Cisneros
J M
JM
Infectious Disease Unit, Virgen del Rocio University Hospital, Seville, Spain.
Viciana
P
P
Colmenero
J
J
Pachón
J
J
Martinez
C
C
Alarcón
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002006:Brucellosis / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D004318:Doxycycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D012008:Recurrence; D013307:Streptomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D004318:Doxycycline; D013307:Streptomycin